GlaxoSmithKline PLC (GSK.L,GSK) and Vir Biotechnology, Inc. (VIR) reported headline data from the randomised, open-label COMET-TAIL phase III trial, which achieved its primary endpoint. The data showed that intramuscular administration of sotrovimab was non-inferior to intravenous administration for the early treatment of mild-to-moderate COVID-19 in high-risk, non-hospitalised adults and adolescents.
Hal Barron, Chief Scientific Officer and President, said: "I am pleased that today's results demonstrated similar efficacy for sotrovimab when injected directly into the muscle compared to administered intravenously, potentially offering a more convenient option for patients. We look forward to working with regulatory authorities to help make this new option available to appropriate patients with COVID-19."
GSK and Vir plan to progress regulatory submissions globally, including ongoing discussions with the FDA regarding the existing Emergency Use Authorization for sotrovimab.
Shares of Vir Biotechnology were up 3% in pre-market trade on Friday.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.